Munich, Germany, December 13, 2010 / b3c newswire / – ProJect Pharmaceutics started business operations and opened its laboratory facilities in the Biotech-cluster in Martinsried, near Munich. ProJect Pharmaceutics (PJP) transforms proteins, peptides and delicate small molecules into pioneering drugs.
Adding value to client´s bio-therapeutic products is PJP´s mission, focused in an innovative concept of biopharmaceutical development called Advaceutics. Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized pharmaceutical formulations and delivery systems that are stable, convenient and safe. Tailored to these optimized systems the company develops cost-effective manufacturing processes and transfers those from its own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational products as well as new presentations of registered drugs are developed effectively and will run smoothly in clinical and commercial scale GMP manufacturing.
ProJect Pharmaceutics was founded and is managed by Andreas Schütz and Klaus Hellerbrand, two leading experts in protein formulation and pharmaceutical process development with many years of experience in bio-pharmaceutics. Their combined expertise and complementary set of qualifications enables ProJect Pharmaceutics to deliver the high-tech pharmaceutical services the team is known for and that are in increased demand for the global biopharmaceutical industry. “In times of an increasingly globalizing and changing pharmaceutical value chain, capital efficiency in developing new drugs, paired with deep expertise and highly reliable quality of service are ever important for competitive pharmaceutical companies facing a challenging market environment”, says Dr. Andreas Schütz, Managing Director and Founder of ProJect Pharmaceutics. “We started our operations with an experienced team of biopharmaceutical professionals and already are working on several exciting projects“, comments Klaus Hellerbrand, Managing Director and Founder.
ProJect Pharmaceutic management profile:
Andreas Schütz, Managing Director & Founder
Andreas Schütz is an inventor of numerous patents and patent applications. His key expertise is focused on Formulation Science, Drug Delivery Systems, Lyophilisation Technology, Aseptic Processing, Project and Key Account Management. He founded ProJect Pharmaceutics in 2010 together with Klaus Hellerbrand. Prior to starting his own company, he was VP Pharmaceutical Development and Head of BioPharma Services at Scil Technologies, Munich, Germany where he had joined in 2001. Dr. Schütz studied Pharmacy and received his PhD in Pharmaceutical Technology from the University of Erlangen in 1991. He began his career in pharmaceutical development with Schwarz Pharma AG, Monheim, Germany and held the position of Head of Specialized Pharmaceutical Systems prior to joining Vetter Pharma, Ravensburg, Germany in 1998 as Head of Pharmaceutical Development and Senior Project Manager.
Klaus Hellerbrand, Managing Director & Founder
Klaus Hellerbrand is an inventor of numerous patents and patent applications. He is an expert in Protein Science, Protein Analytics, Down-stream Processing, Process Technology, Coating Technology and Lyophilisation Technology. He founded ProJect Pharmaceutics in 2010 together with Dr. Andreas Schütz. Prior to his entrepreneurial activity he worked as Head of Pharmaceutical Technology at Scil Technology, Munich, Germany where he joined in 1999 as protein formulation scientist. Klaus Hellerbrand earned his degree of applied Science in Biotechnology from the University of Weihenstephan. In 1995 he joined Boehringer Mannheim/ Roche Diagnostics as a development engineer focused on down-stream processes for protein drugs and development of protein formulations.
For more information please visit: www.project-pharmaceutics.com or contact:
ProJect Pharmaceutics GmbH
+49 (0) 89 452289700
Dr. Andreas Schütz: firstname.lastname@example.org
Klaus Hellerbrand: email@example.com
+49 (0)8141 539702